Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance
DG Hernandez, X Reed… - Journal of …, 2016 - Wiley Online Library
Parkinson's disease is a common, progressive neurodegenerative disorder, affecting 3% of
those older than 75 years of age. Clinically, Parkinson's disease (PD) is associated with …
those older than 75 years of age. Clinically, Parkinson's disease (PD) is associated with …
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences
N Exner, AK Lutz, C Haass, KF Winklhofer - The EMBO journal, 2012 - embopress.org
Neurons are critically dependent on mitochondrial integrity based on specific morphological,
biochemical, and physiological features. They are characterized by high rates of metabolic …
biochemical, and physiological features. They are characterized by high rates of metabolic …
Structure of LRRK2 in Parkinson's disease and model for microtubule interaction
Leucine-rich repeat kinase 2 (LRRK2) is the most commonly mutated gene in familial
Parkinson's disease and is also linked to its idiopathic form. LRRK2 has been proposed to …
Parkinson's disease and is also linked to its idiopathic form. LRRK2 has been proposed to …
LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network
Human genetic studies implicate LRRK2 and RAB7L1 in susceptibility to Parkinson disease
(PD). These two genes function in the same pathway, as knockout of Rab7L1 results in …
(PD). These two genes function in the same pathway, as knockout of Rab7L1 results in …
Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations
Z Sheng, S Zhang, D Bustos, T Kleinheinz… - Science translational …, 2012 - science.org
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common cause of
familial Parkinson's disease (PD). Although biochemical studies have shown that certain PD …
familial Parkinson's disease (PD). Although biochemical studies have shown that certain PD …
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice
Mutations in the LRRK2 gene represent the most common genetic cause of late onset
Parkinson's disease. The physiological and pathological roles of LRRK2 are yet to be fully …
Parkinson's disease. The physiological and pathological roles of LRRK2 are yet to be fully …
LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1
X Wang, MH Yan, H Fujioka, J Liu… - Human molecular …, 2012 - academic.oup.com
The leucine-rich repeat kinase 2 (LRRK2) mutations are the most common cause of
autosomal-dominant Parkinson disease (PD). Mitochondrial dysfunction represents a critical …
autosomal-dominant Parkinson disease (PD). Mitochondrial dysfunction represents a critical …
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
MR Cookson - Nature Reviews Neuroscience, 2010 - nature.com
Parkinson's disease, like many common age-related conditions, is now recognized to have a
substantial genetic component. Here, I discuss how mutations in a large complex gene …
substantial genetic component. Here, I discuss how mutations in a large complex gene …
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
RJ Nichols, N Dzamko, NA Morrice… - Biochemical …, 2010 - portlandpress.com
LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of
Parkinson's disease patients, but still little is understood about how it is regulated or …
Parkinson's disease patients, but still little is understood about how it is regulated or …
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization
LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of
Parkinson's disease patients. Since a common mutation that replaces Gly2019 with a serine …
Parkinson's disease patients. Since a common mutation that replaces Gly2019 with a serine …